Table 1.
Prevalence of PSM for individual tumor sites as a function of gender, race, age, tumor category, tumor grade. Analysis of PSM change over study period comparing unadjusted rate from the last 5 years of the study period 2008–2012 to the first 5 years of the study period (1998–2002).
| BREAST (LUMP, MAST, TOTAL) | PROSTATE | BLADDER | COLON & RECTUM | THYROID | ORAL CAVITY | LUNG & BRONCHUS | KIDNEY & RENAL PELVIS | UTERINE | OVARIAN | TOTAL | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Cases (n) | 1,479,230 | 1,051,335 | 2,530,565 | 761,637 | 241,791 | 1,218,834 | 314,459 | 120,826 | 462,482 | 361,240 | 391,997 | 92,058 | 6,495,889 |
| Number of PSM Cases | 97,335 | 55,746 | 153,081 | 160,194 | 23,317 | 83,241 | 36,230 | 15,411 | 33,861 | 20,691 | 16,938 | 32,217 | 575,181 |
| Overall PSM Rate (%) | 6.58 | 5.30 | 6.05 | 21.03 | 9.64 | 6.83 | 11.52 | 12.75 | 7.32 | 5.73 | 4.32 | 35.00 | 8.85% |
| Gender | |||||||||||||
| Men | 8.30 | 4.47 | 5.53 | 21.03 | 8.96 | 6.71 | 13.24 | 12.65 | 8.00 | 6.04 | N/A | N/A | 7.73% (109,572)a |
| Women | 6.57 | 5.32 | 6.05 | N/A | 11.58 | 6.95 | 10.99 | 12.92 | 6.64 | 5.23 | 4.32 | 35.00 | 6.69% (256,260)a |
| Race | |||||||||||||
| White | 6.32 | 5.08 | 5.81 | 20.60 | 9.31 | 6.66 | 10.90 | 12.30 | 7.15 | 5.80 | 3.86 | 35.67 | 8.60% (424,725) |
| Black/AA | 7.93 | 6.53 | 7.32 | 23.19 | 14.19 | 7.43 | 8.76 | 18.62 | 8.53 | 4.99 | 7.90 | 33.47 | 10.04% (58,393) |
| Other | 7.28 | 5.68 | 6.57 | 22.21 | 9.20 | 7.12 | 15.32 | 13.62 | 7.46 | 5.82 | 4.78 | 27.81 | 9.34% (19,087) |
| Latino/Hisp | 7.07 | 5.53 | 6.41 | 21.65 | 10.28 | 7.34 | 14.53 | 13.15 | 7.83 | 5.84 | 4.66 | 33.86 | 9.47% (72,976) |
| Age | |||||||||||||
| <40 | 8.62 | 6.32 | 7.33 | 17.17 | 6.94 | 9.78 | 10.43 | 10.56 | 9.56 | 4.20 | 3.52 | 15.64 | 8.42% (28,867) |
| 41–80 | 6.15 | 5.12 | 5.73 | 21.08 | 8.78 | 6.75 | 11.60 | 12.70 | 7.25 | 5.72 | 4.16 | 36.49 | 8.89% (494,280) |
| >81 | 10.18 | 6.14 | 8.45 | 17.07 | 13.41 | 6.68 | 23.78 | 14.09 | 7.79 | 7.10 | 6.78 | 42.76 | 8.74% (52,034) |
| T-category | |||||||||||||
| In Situ | 5.67 | 3.19 | 4.89 | 0.00 | 3.30 | 1.41 | 0.00 | 9.33 | 4.80 | 3.26 | 0.58 | N/A | 4.39% (26,766) |
| T1 | 5.63 | 3.74 | 4.99 | 19.02 | 6.24 | 2.74 | 5.21 | 7.85 | 3.05 | 2.87 | 1.00 | 3.94 | 5.96% (167,291) |
| T2 | 9.13 | 5.27 | 6.97 | 19.58 | 17.37 | 1.92 | 8.26 | 14.92 | 6.77 | 2.73 | 5.87 | 27.78 | 8.50% (110,683) |
| T3 | 20.11 | 9.55 | 11.05 | 45.95 | 24.07 | 5.61 | 24.79 | 20.32 | 19.57 | 14.17 | 25.70 | 58.25 | 11.26% (100,539) |
| T4 | 37.60 | 18.58 | 20.89 | 65.54 | 40.33 | 27.05 | 50.76 | 25.18 | 27.13 | 42.04 | 51.89 | N/A | 29.96% (77,740) |
| Grade | |||||||||||||
| Well Differentiated | 5.19 | 4.14 | 4.85 | 9.64 | 2.41 | 4.68 | 9.10 | 9.70 | 4.45 | 2.73 | 0.02 | 10.35 | 4.47% (44,669) |
| Mod Differentiated | 6.66 | 5.23 | 6.07 | 15.99 | 4.75 | 5.82 | 19.52 | 13.81 | 6.32 | 3.61 | 2.53 | 25.98 | 7.51% (195,187) |
| Poorly Differentiated | 7.21 | 5.94 | 6.59 | 27.31 | 14.47 | 12.47 | 32.77 | 18.61 | 8.71 | 8.44 | 10.77 | 45.22 | 13.11% (229,211) |
| Undifferentiated | 8.45 | 6.95 | 7.76 | 31.51 | 16.26 | 15.54 | 61.89 | 20.57 | 9.91 | 16.28 | 15.58 | 48.31 | 16.46% (24,681) |
| Change over study period | |||||||||||||
| Men |
−3.22**
(−3.96:−2.47) |
−0.213
(−0.44:0.02) |
2.95**
(2.62:3.27) |
2.41**
(2.25:2.56) |
−0.775*
(−1.43:−0.12) |
−0.252
(−0.83:0.33) |
−0.374*
(−0.65:−0.10) |
1.44**
(1.18–1.70) |
NA | NA | |||
| Women |
−3.63**
(−3.70:−3.55) |
NA |
3.72**
(3.11:4.33) |
2.38**
(2.23:2.54) |
0.528*
(−0.12:0.19) |
−1.15*v(−1.89:−0.41) |
−0.74**
(−0.99:−0.49) |
1.19**
(0.88:1.49) |
0.481**
(0.33–0.64) |
−4.59**
(−5.2:−3.97) |
|||
a. Only tumors occurring in both genders are included here.
b. Numbers given are percents unless otherwise indicated. *p < 0.05; **p < 0.001, Not applicable (NA).